The Effect of 3'-Hydroxy-3,4,5,4'-Tetramethoxy -stilbene, the Metabolite of the Resveratrol Analogue DMU-212, on the Motility and Proliferation of Ovarian Cancer Cells.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Cell Movement/*drug effects ; Cell Proliferation/*drug effects ; Ovarian Neoplasms/*metabolism ; Resveratrol/*analogs & derivatives ; Stilbenes/*pharmacology; Cell Line, Tumor ; Female ; Humans ; Kruppel-Like Factor 4 ; Stilbenes/metabolism ; Transcriptome

Targeting tumor cell motility and proliferation is an extremely important challenge in the prevention of metastasis and improving the effectiveness of cancer treatment. We recently published data revealing that DMU-214, the metabolite of firmly cytotoxic resveratrol analogue DMU-212, exerted significantly higher biological activity than the parent compound in ovarian cancer cells. The aim of the present study was to assess the molecular mechanism of the potential anti-migration and anti-proliferative effect of DMU-214 in ovarian cancer cell line SKOV-3. We showed that DMU-214 reduced the migratory capacity of SKOV-3 cells. The microarray analysis indicated ontology groups of genes involved in processes of negative regulation of cell motility and proliferation. Furthermore, we found DMU-214 triggered changes in expression of several migration- and proliferation-related genes (SMAD7, THBS1, IGFBP3, KLF4, Il6, ILA, SOX4, IL15, SRF, RGCC, GPR56) and proteins (GPR56, RGCC, SRF, SMAD7, THBS1), which have been shown to interact to each other to reduce cell proliferation and motility. Our study showed for the first time that DMU-214 displayed anti-migratory and anti-proliferative activity in SKOV-3 ovarian cancer cells. On the basis of whole transcriptome analysis of these cells, we provide new insight into the role of DMU-214 in inhibition of processes related to metastasis.

Adv Clin Exp Med. 2018 Jun;27(6):735-742. (PMID: 29790697)
Int J Mol Sci. 2018 Apr 07;19(4):. (PMID: 29642441)
BMC Cancer. 2015 Dec 16;15:969. (PMID: 26674205)
Genome Biol. 2003;4(5):P3. (PMID: 12734009)
Bioinformatics. 2010 Oct 1;26(19):2363-7. (PMID: 20688976)
Anticancer Res. 2011 Mar;31(3):897-906. (PMID: 21498711)
Front Endocrinol (Lausanne). 2017 Feb 15;8:26. (PMID: 28261157)
Sci Rep. 2016 Sep 02;6:32627. (PMID: 27585955)
Biomed Pharmacother. 2014 May;68(4):397-400. (PMID: 24768110)
Int J Mol Sci. 2019 Oct 30;20(21):. (PMID: 31671654)
Int J Mol Sci. 2018 Aug 03;19(8):. (PMID: 30081524)
BMC Res Notes. 2014 Mar 27;7:183. (PMID: 24674422)
Toxicol In Vitro. 2013 Dec;27(8):2127-34. (PMID: 24055891)
J Mol Cell Biol. 2017 Oct 1;9(5):352-363. (PMID: 28992202)
Am Fam Physician. 2016 Jun 1;93(11):937-44. (PMID: 27281838)
J Biol Chem. 2006 Jul 21;281(29):20383-92. (PMID: 16690609)
Front Genet. 2017 Jan 25;8:1. (PMID: 28179914)
Blood. 2011 Sep 1;118(9):2622-31. (PMID: 21551235)
Bioinformatics. 2004 Feb 12;20(3):307-15. (PMID: 14960456)
J Clin Invest. 2013 May;123(5):2193-206. (PMID: 23563308)
Pharm Biol. 2016;54(4):660-6. (PMID: 26428916)
FASEB J. 2004 Aug;18(11):1264-6. (PMID: 15180964)
Calcif Tissue Int. 2018 Jan;102(1):117-127. (PMID: 29038881)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Int J Mol Sci. 2019 Feb 20;20(4):. (PMID: 30791624)
Nat Genet. 2004 Jul;36(7):663; author reply 663. (PMID: 15226741)
PLoS One. 2010 Nov 15;5(11):e13984. (PMID: 21085593)
J Biol Chem. 2016 Feb 12;291(7):3385-94. (PMID: 26710850)
Oncol Rep. 2018 Oct;40(4):1885-1896. (PMID: 30066935)
Cell Mol Biol Lett. 2016 Sep 20;21:19. (PMID: 28536621)
PLoS One. 2019 Jan 17;14(1):e0210607. (PMID: 30653610)
Toxicol Appl Pharmacol. 2012 Aug 15;263(1):53-60. (PMID: 22687606)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503. (PMID: 31691815)
Br J Pharmacol. 2010 Jul;160(6):1352-61. (PMID: 20590626)
Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56. (PMID: 26224579)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
Bioinformatics. 2013 Nov 1;29(21):2810-1. (PMID: 23958726)
Int J Cancer. 2005 Jun 10;115(2):194-201. (PMID: 15688382)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
F1000Res. 2016 Jul 15;5:1717. (PMID: 27830058)
Angiogenesis. 2010 Dec;13(4):305-15. (PMID: 20927579)
J Hematol Oncol. 2016 Sep 29;9(1):101. (PMID: 27686372)
Front Oncol. 2013 Oct 29;3:269. (PMID: 24195060)
Eur J Med Chem. 2011 Jun;46(6):2586-95. (PMID: 21497957)
Br J Cancer. 2005 Feb 14;92(3):513-21. (PMID: 15668717)
J Food Drug Anal. 2017 Jan;25(1):134-147. (PMID: 28911531)
Cancer Res. 2001 Jan 1;61(1):383-91. (PMID: 11196191)
Drug Discov Today. 2010 Sep;15(17-18):757-65. (PMID: 20692359)
Cell Adh Migr. 2009 Jul-Sep;3(3):264-7. (PMID: 19287204)
Am J Physiol Heart Circ Physiol. 2009 Apr;296(4):H1027-37. (PMID: 19168719)
Cancer Res. 2011 Aug 1;71(15):5276-86. (PMID: 21653679)
Int J Mol Sci. 2019 Mar 19;20(6):. (PMID: 30893846)
Br J Cancer. 2004 Feb 9;90(3):736-44. (PMID: 14760392)
Gynecol Oncol. 2007 Apr;105(1):104-12. (PMID: 17174384)
Nutrients. 2016 Apr 14;8(4):222. (PMID: 27089363)
Am J Pathol. 2010 Sep;177(3):1053-64. (PMID: 20651229)
Food Chem Toxicol. 2017 May;103:122-132. (PMID: 28279696)
Toxicology. 2019 Jun 15;422:35-43. (PMID: 31004704)
J Biol Chem. 2013 Aug 16;288(33):23868-74. (PMID: 23846700)
Cancer Chemother Pharmacol. 2008 Dec;63(1):27-35. (PMID: 18286288)

2016/23/D/NZ7/03954 Narodowe Centrum Nauki

Keywords: DMU-214; migration; ovarian cancer; proliferation; resveratrol analogue

0 (3,4,5,4'-tetramethoxystilbene)
0 (KLF4 protein, human)
0 (Kruppel-Like Factor 4)
0 (Stilbenes)
Q369O8926L (Resveratrol)

Date Created: 20200213 Date Completed: 20201118 Latest Revision: 20211204

20250114

PMC7037107

10.3390/ijms21031100

32046103